Related references
Note: Only part of the references are listed.Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)- related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management
Sandra M. Swain et al.
CANCER TREATMENT REVIEWS (2022)
Management ofAbemaciclib-AssociatedAdverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis ofMONARCH2 andMONARCH3
Hope S. Rugo et al.
ONCOLOGIST (2021)
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
M. E. Lacouture et al.
ANNALS OF ONCOLOGY (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Trends in kinase drug discovery: targets, indications and inhibitor design
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Clinical Management of Adverse Events Associated with Lorlatinib
Todd M. Bauer et al.
ONCOLOGIST (2019)
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Bruno C. Medeiros et al.
BLOOD REVIEWS (2018)
Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs
Carmela Coppola et al.
CANCER TREATMENT REVIEWS (2018)
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Mario Lacouture et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis
Julia Dai et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies
Matthieu Picard et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Cutaneous manifestations of nontargeted and targeted chemotherapies
Veronica J. Shi et al.
SEMINARS IN ONCOLOGY (2016)
Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management
B. McLellan et al.
ANNALS OF ONCOLOGY (2015)
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials
Matteo Santoni et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis
Omar Abdel-Rahman et al.
FUTURE ONCOLOGY (2015)
Papulopustular Acneiform Eruptions Resulting From Trastuzumab, a HER2 Inhibitor
Johanna Sheu et al.
Clinical Breast Cancer (2014)
Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
Alyx C. Rosen et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2013)
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer
Yoshio Kiyohara et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
Courtney J. Ensslin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses
Brian A. Baldo
ONCOIMMUNOLOGY (2013)
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
L. Albiges et al.
ANNALS OF ONCOLOGY (2012)
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
Cristina Gomez-Fernandez et al.
EUROPEAN JOURNAL OF CANCER (2012)
The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis
Benjamin C. Garden et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
Xiao Feng Hang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Mario E. Lacouture et al.
SUPPORTIVE CARE IN CANCER (2011)
Common toxicities of mammalian target of rapamycin inhibitors
Scott A. Soefje et al.
TARGETED ONCOLOGY (2011)
Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy
B. Nardone et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
M. E. Lacouture et al.
ANNALS OF ONCOLOGY (2008)
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
Julien Autier et al.
ARCHIVES OF DERMATOLOGY (2008)
Chemotherapeutic agents and the skin: An update
Noushin Heidary et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
Thomas J. Lynch et al.
ONCOLOGIST (2007)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
Share Paper
